PharmaLectures.com

Courses › Country and business playbooks › Selling into Europe as a biologics and biosimilars maker from Egypt, Gulf and MENA

Selling into Europe as a biologics and biosimilars maker from Egypt, Gulf and MENA

Your team answers European buyers on compliance the same day, without waiting for legal.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Egypt, Gulf and MENA, Biologics and biosimilarswho it is written for

Why this training matters

A distributor in Hamburg asks which European Medicines Agency guideline your biosimilar follows. Nobody on the call knows. The question goes to regulatory, the answer comes back late, and the distributor has already signed with another supplier.

What changes after this course

Your team answers questions on centralised authorisation, Good Manufacturing Practice and pricing without waiting for legal. Market access plans reflect national reimbursement rules from the start. You hold a certificate per learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory team stops guessing which route a product takes. They know when the centralised procedure is mandatory, what the European Medicines Agency decides and what each national competent authority still decides. They file the Marketing Authorisation Application in the right order, and they classify a biosimilar against its reference product before the first query arrives.

Manufacturing and quality directors walk their own plant through EudraLex Volume 4 before an inspector does. The Qualified Person has a batch file that answers what Annex 16 requires before certification and release. Your clinical writers place non-clinical data in Module 4 and clinical data in Module 5 of the Common Technical Document, so reviewers find the proof where they look for it.

Safety reporting turns into routine work. The Qualified Person for pharmacovigilance sees the reports they need, and Periodic Safety Update Reports reach the agency's repository on time. Market access leads build pricing cases for the health technology assessment bodies in Germany and France before the first submission, not after the first refusal.

Sales representatives walk into meetings with European opinion leaders and patient groups holding a plan that fits local etiquette. Your legal team reads originators' patents and Supplementary Protection Certificates before you set a launch date. Export managers answer a distributor's cold chain and customs questions in the room, and the deal moves on.

Who needs this training

  • Head of Regulatory Affairs

    Validation queries land on a dossier laid out the wrong way, and the team spends weeks reformatting the Common Technical Document. You learn the route and the layout before you file, not after.

  • Pharmaceutical Export Manager

    A European distributor asks about your pharmacovigilance system master file and your inspection history during due diligence. You answer in the meeting instead of promising to come back with legal's reply.

  • Market Access Lead

    You prepare a price for Germany and then watch parallel trade from a cheaper country undercut it. You go into health technology assessment talks knowing what each body asks for first.

  • Quality Assurance Director

    A European inspection is on the calendar and you need a working checklist built on EudraLex Volume 4, not a late-night read of the whole volume. You walk the plant with one in hand.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: Biologics and biosimilars

Countries: Egypt, Gulf and MENA

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Decide whether a product must use the centralised procedure and name what the national authority still handles.
  2. Classify a product as a reference biological or a biosimilar and name the guideline that applies to it.
  3. Check your plant against EudraLex Volume 4 and list the gaps an inspector would find first.
  4. Place non-clinical data in Module 4 and clinical data in Module 5 of the Common Technical Document.
  5. Outline a pharmacovigilance system master file and state the reporting deadlines for suspected adverse reactions.
  6. Read an originator's Supplementary Protection Certificate and set a biosimilar launch date from it.
  7. Prepare a pricing case for a health technology assessment body in Germany or France.

What the company gets

  • Your regulatory team files the Marketing Authorisation Application on the right route, with a dossier laid out the way reviewers expect.
  • Your plant has a gap list against EudraLex Volume 4 before the inspector arrives, so there is time to close it.
  • Distributors get straight answers on compliance, cold chain and customs in the first meeting, and your export manager no longer waits for legal.
  • Your pharmacovigilance reports reach the agency on time, with a Qualified Person who has access to the files they sign for.
  • Your sales team stops losing distribution talks to cultural misreads, and the training record shows who completed which module.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Read the European biologics market and pick your first country to enter

    • Why a plan built for Egypt or the Gulf fails in Germany, and what to change before the first meeting.
    • How to tell where one European authorisation covers you and where each country still decides for itself.
    • The first-market choice you can defend to your board, because you know how national health systems pay.
  2. 2Work with the European Medicines Agency and national competent authorities

    • When the centralised procedure is mandatory for your product, and what national authorities still handle.
    • Which questions go to the European Medicines Agency and which go to a national authority.
    • What the Pharmacovigilance Risk Assessment Committee asks for, so your answer is ready before the request.
  3. 3Classify your product as reference biological or biosimilar

    • How the European definition of a biological medicine decides which studies you must run.
    • The line between a reference product and a biosimilar, and why a dossier that blurs it gets questions.
    • Why the European Medicines Agency guideline on monoclonal antibody biosimilars sets your development plan.
  4. 4Submit a Marketing Authorisation Application that clears validation

    • How to lay out the application so validation has little to query.
    • The product types for which the centralised procedure is mandatory, so you never file on the wrong route.
    • What to do when the agency's list of questions arrives and the clock stops for your reply.
  5. 5Bring your site into line with EudraLex Volume 4 before inspectors visit

    • How to walk your own plant through EudraLex Volume 4 before an inspector does.
    • The first records a European inspector asks for, and where to keep them so they appear in minutes.
    • What the Qualified Person needs in the batch file under Annex 16 before releasing to Europe.
  6. 6Format clinical data for the Common Technical Document reviewers expect

    • Where non-clinical data goes in Module 4 and clinical data in Module 5 of the Common Technical Document.
    • The trial design details that show reviewers your biosimilar matches the reference product.
    • What to put in the Module 2 summaries so a reviewer sees the case for biosimilarity before the data.
  7. 7Set up a pharmacovigilance system that passes European inspection

    • How to write the pharmacovigilance system master file so an inspector finds every answer in it.
    • The reporting deadlines for suspected adverse reactions, so no case reaches the agency late.
    • Why the Qualified Person for pharmacovigilance must see certain reports, and how to give them access.
  8. 8Build pricing and reimbursement cases that national assessment bodies accept

    • How national bodies weigh a biosimilar's value for pricing and reimbursement, and what evidence they ask for.
    • The pricing approaches that suit Germany and France, and why one price for all of Europe fails.
    • What a national reimbursement authority needs on your desk before it will agree a price.
  9. 9Plan cold chain and customs so shipments reach European buyers intact

    • How to plan cold chain handling from an Egyptian or Gulf plant to a European warehouse.
    • The customs steps that hold up pharmaceutical shipments at a European border, and how to prepare for them.
    • What parallel trade does to your price in one country when another country pays less.
  10. 10Secure your launch against patents and Supplementary Protection Certificates

    • How to read an originator's Supplementary Protection Certificate and set your launch date by it.
    • The data protection period on a reference biological, and how it limits when you can file and sell.
    • What to do when your product risks infringing a European patent, before the claim letter arrives.
  11. 11Engage opinion leaders, patient groups and clinicians with the right message

    • How to open with a European Key Opinion Leader so the talk starts with their patients.
    • The needs of patient advocacy groups that should shape what you say and what you leave out.
    • What European clinicians expect in a sales presentation, and the claims that cost you the room.
  12. 12Adapt your meetings and negotiations to European business norms

    • How Gulf negotiating habits differ from those of European buyers, and what to adjust before you sit down.
    • The etiquette points that decide whether the first meeting goes well.
    • Why a small cultural misread can stall a distribution contract, and how to spot it mid-meeting.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Egypt, Gulf and MENA, Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team